Overview

  • Product nameAnti-B Raf antibody
    See all B Raf primary antibodies
  • Description
    Rabbit polyclonal to B Raf
  • Tested applicationsELISA, WB, ICC/IF, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide derived from an internal sequence of human B Raf.

  • Positive control
    • Human brain tissue, HeLa cell extracts and HUVEC cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab65050 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/20000.
WB 1/500 - 1/1000. Detects a band of approximately 55 kDa (predicted molecular weight: 85 kDa).
ICC/IF 1/500 - 1/1000.
IHC-P 1/50 - 1/100.

Target

  • FunctionInvolved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron.
  • Tissue specificityBrain and testis.
  • Involvement in diseaseNote=Defects in BRAF are found in a wide range of cancers.
    Defects in BRAF may be a cause of colorectal cancer (CRC) [MIM:114500].
    Defects in BRAF are involved in lung cancer (LNCR) [MIM:211980].
    Defects in BRAF are involved in non-Hodgkin lymphoma (NHL) [MIM:605027]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.
    Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
    Defects in BRAF are the cause of Noonan syndrome type 7 (NS7) [MIM:613706]. Noonan syndrome is a disorder characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.
    Defects in BRAF are the cause of LEOPARD syndrome type 3 (LEOPARD3) [MIM:613707]. LEOPARD3 is a disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
    Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation.
  • Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily.
    Contains 1 phorbol-ester/DAG-type zinc finger.
    Contains 1 protein kinase domain.
    Contains 1 RBD (Ras-binding) domain.
  • Cellular localizationNucleus. Cytoplasm. Cell membrane. Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes.
  • Information by UniProt
  • Database links
  • Alternative names
    • FLJ95109 antibody
    • 94 kDa B raf protein antibody
    • B raf 1 antibody
    • B Raf proto oncogene serine threonine protein kinase antibody
    • B-Raf proto-oncogene serine/threonine-protein kinase (p94) antibody
    • BRAF 1 antibody
    • BRAF antibody
    • BRAF_HUMAN antibody
    • BRAF1 antibody
    • cRmil antibody
    • MGC126806 antibody
    • MGC138284 antibody
    • Murine sarcoma viral (v-raf) oncogene homolog B1 antibody
    • Murine sarcoma viral v raf oncogene homolog B1 antibody
    • NS7 antibody
    • oncogene BRAF1 antibody
    • p94 antibody
    • Proto-oncogene B-Raf antibody
    • Proto-oncogene c-Rmil antibody
    • RAFB 1 antibody
    • RAFB1 antibody
    • RMIL antibody
    • Serine/threonine-protein kinase B-raf antibody
    • v raf murine sarcoma viral oncogene homolog B antibody
    • v raf murine sarcoma viral oncogene homolog B1 antibody
    • v-Raf murine sarcoma viral oncogene homolog B1 antibody
    see all

Anti-B Raf antibody images

  • ab65050 at 1/50 dilution staining B Raf in human brain by Immunohistochemistry, Paraffin-embedded tissue, in the absence or presence of the immunising peptide.
  • All lanes : Anti-B Raf antibody (ab65050) at 1/500 dilution

    Lane 1 : HeLa cell extract
    Lane 2 : HeLa cell extract with immunising peptide at 5 µg

    Lysates/proteins at 5 µg per lane.


    Predicted band size : 85 kDa
    Observed band size : 55 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 60 kDa. We are unsure as to the identity of these extra bands.
  • ab65050 at 1/500 dilution staining B Raf in HUVEC cells by Immunofluorescence, in the absence or presence of the immunising peptide.

References for Anti-B Raf antibody (ab65050)

ab65050 has not yet been referenced specifically in any publications.

Product Wall

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Mouse Tissue sections (brain)
Specification brain
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: HIER Citric acid pH6
Permeabilization No
Blocking step BSA as blocking agent for 10 minute(s) · Concentration: 1% · Temperature: rt°C
Username

Mr. Carl Hobbs

Verified customer

Submitted Feb 02 2009

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"